On Monday, Flotek Industries Inc (NYSE:FTK)’s shares declined -1.29% to $16.90.
Flotek Industries, Inc. (FTK) declared results for the three months ended June 30, 2015.
As stated on Form 10-Q filed with the U.S. Securities and Exchange Commission, Flotek stated that revenue for the three months ended June 30, 2015, was $87.0 million contrast to $105.3 million for the three months ended June 30, 2014 and $82.4 million for the first quarter of 2015. Second quarter, 2015 revenue raised 5.6% sequentially but reduced 17.4% when contrast to the same period in 2014. The decrease in year-over-year revenue was driven by the steep decline in oilfield activity; however, the enhance in sequential revenue was driven almost entirely by raised sales of Flotek’s Complex nano-Fluid® completion chemistries as the Company’s marketing campaign and new direct distribution model offered noteworthy revenue opportunities during the quarter.
For the three months ended June 30, 2015, the Company stated net income (not taking into account non-cash charges) of $1.1 million, or $0.02 per common share (fully diluted), contrast to net income of $11.0 million, or $0.20 per common share (fully diluted) for the same period in 2014 and a net loss of $1.5 million or $0.03 per common share (fully diluted) in the first quarter of this year.
Flotek Industries, Inc. develops and supplies oilfield products, services, and equipment to the oil, gas, and mining industries in the United States and internationally. Its Energy Chemical Technologies segment designs, develops, manufactures, packages, and markets specialty chemicals used in oil and gas well drilling, cementing, completion, stimulation, and production. This segment also constructs and manages automated material handling facilities; and manages loading facilities and blending operations for oilfield services companies.
Galena Biopharma Inc (NASDAQ:GALE)’s shares dropped -0.61% to $1.63.
Galena Biopharma, Inc. (GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, recently declared the product launch for Zuplenz(R)(ondansetron) Oral Soluble Film in the United States.
Zuplenz is now accessible nationwide and is supplied in both 4 mg and 8 mg strengths. Zuplenz is clinically bioequivalent to ondansetron orally disintegrating tablets (ODT) with a safety profile equivalent to ondansetron. The novel, PharmFilm(R) oral soluble film technology utilized by Zuplenz provides for convenient delivery and several key patient benefits counting:
- Rapidly dissolves in the mouth in about 10 seconds
- Eliminates the burden of swallowing pills during emesis and in cases of oral irritation
- Does not require water to administer
- Pleasant peppermint flavor with no gritty aftertaste
- Non-sedating
Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology therapeutics that address major unmet medical needs across cancer care. Its commercial products comprise Abstral, a sublingual tablet that is used for the administration of breakthrough pain in patients with cancer; and Zuplenz, an oral soluble film for use in the prevention of chemotherapy-induced, radiotherapy-induced, and post-operative nausea and vomiting.
At the end of Monday s trade, MakeMyTrip Limited (NASDAQ:MMYT)‘s shares dipped -3.56% to $14.08.
MakeMyTrip, India`s leading online travel company, declared signing of agreement for the acquisition of a minority stake in HolidayIQ, a popular Indian travel community and holidays-planning recommendation engine. The company will pick up around 28% stake in HolidayIQ for $15 million. The transaction is planned to complete in July 2015. This planned investment will enable both companies to rapidly scale up hotel content and reviews for Indian customers, and provide more compelling offerings to their visitors.
According to HolidayIQ, the funds will mainly be used to further strengthen its capabilities on Content, Mobile and Product. HolidayIQ had raised series A before from Tiger Global and Accel Partners. The focus at HolidayIQ is to become the “authentic voice of Indian travellers, by encouraging all Indian travellers to share reviews & express opinion on all their travel”. Presently, HolidayIQ has over a million holiday reviews from Indian travellers which it anticipates to enhance over the next two years.
MakeMyTrip Limited, an online travel company, provides travel products and solutions in India and internationally. The company operates in two segments, Air Ticketing, and Hotels and Packages. Its services and products comprise air tickets, hotels, packages, rail tickets, bus tickets, car hire, and ancillary travel requirements, such as facilitating access to travel insurance and visa processing.
Tower Semiconductor Ltd. (USA) (NASDAQ:TSEM), ended its Monday’s trading session with -4.30% loss, and closed at $12.69.
TowerJazz, the global specialty foundry leader, recently declared it is ramping high volume production of a touch screen controller developed by N-trig, an Israeli company. Recently, this advanced digital pen technology was attained by Microsoft for use with its Surface products. The touch screen controller, which enables special capabilities of sensing multi-fingers touch and a digital pen (stylus), will be produced using TowerJazz’s advanced 0.18-micron power administration process (TS18PM). N-trig’s ICs were designed by N-trig with the support of TowerJazz’s Netanya Design Center (NDC) in Israel and are being manufactured in its Migdal Haemek, Israel fabrication facility (Fab 2).
Tower Semiconductor Ltd., an independent semiconductor foundry, manufactures analog intensive mixed-signal semiconductor devices in the United States, Asia, and Europe. It produces integrated circuits (ICs) primarily based on third party designs, in addition to provides design support and related technical services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
